Pemafibrate（Parmodia^®）是高效的過氧化物酶體增殖激活受體α（PPARα）激動劑，通過選擇性結(jié)合PPARα受體調(diào)控PPARα的表達(dá)，從而增加高密度脂蛋白的含量和降低血漿中的三酰甘油水平。該藥由日本興和集團(tuán)研制，并在2017年7月3日被批準(zhǔn)上市，在日本用于治療高血脂癥。就Pemafibrate的化學(xué)性質(zhì)、作用機(jī)制、藥動學(xué)和臨床研究等進(jìn)行概述，以期為臨床用藥提供幫助。

Pemafibrate (Parmodia^®) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α agonist. It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby leading the reduced plasma triglyceride levels and the increased high-density lipoprotein cholesterol levels. Oral pemafibrate developed by Kowa Company has been approved in Japan on July 3, 2017 for the treatment of hyperlipidemia. The properties, pharmacokinetics, pharmacodynamics, and clinical trials about pemafibrate in the review are introduced to guide the doctors and the patients.